Cannabis Science's Mieko Hester-Perez Confirms CBIS Premiere Sponsorship Role at "We Cann Mix," a Diverse Cannabis Community and Business Mixer Event in Los Angeles, CA
LOS ANGELES, CA--(Marketwired - Jun 23, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced their sponsorship of the "We Cann Mix" event, which is a mixer event intended for patients, advocates, entrepreneurs, scientists, and other enthusiastic members of the cannabis community.
The Joey Network App in collaboration with CannILiv are the primary hosts of this event. The fact The Joey Network App is involved, is one of the reasons Cannabis Science was able to attain such a premiere sponsorship opportunity at the event. The Joey Network App is Cannabis Science Scientific Advisory Board Member Mieko Hester-Perez's cannabis treatment-centered smartphone app.
The event, which is happening during Black Entertainment TV (BET) Weekend, will be hosted at The Bonaventure Brewing Company in Los Angeles, CA on Friday, June 24, 2016 at 7:00 pm.
Tickets are available at https://www.eventbrite.com/e/we-cann-mix-an-experience-in-diversity-tickets-25868211517?aff=eac2
The event will offer networking opportunities for anyone with a foot in the industry. In addition to the business networking opportunities at this event, guests will enjoy a cocktail mixer with light appetizers. Gift bags, business start-up/information exhibitions, and industry-leading guest speakers to figure prominently as well.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.